-
-
-
-
-
-
-
Moonlake Immunotherapeutics (MLTX) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
BTIG on Moonlake Immunotherapeutics (MLTX): 'An Underappreciated and Large Market Opportunity in Rheumatology'
-
-
-
-
-
-
-
MoonLake prices $75 million stock offering at $10.50 per share
-
-
-
-
-
-
-
Moonlake Immunotherapeutics (MLTX) PT Lowered to $20 at Guggenheim, removed as Best Idea
-
-
-
-
-
-
-
RBC Capital Downgrades Moonlake Immunotherapeutics (MLTX) to Sector Perform
-
-
-
-
-
-
-
MoonLake Immunotherapeutics (MLTX) call put ratio 1 call to 9 puts as share price down 4.7%
-
-
-
-
-
-
-
MoonLake Immunotherapeutics (MLTX) Tops Q1 EPS by 13c
-
423,284 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

